NCT01283542

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.

Conditions

• Non-functioning Pituitary Adenoma

Interventions

Type	Name	Description
DRUG	Pasireotide LAR	20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection

Timeline

• Start date: 2012-11-26
• Primary completion: 2017-09-12
• Completion: 2017-09-12
• First posted: 2011-01-26
• Last updated: 2019-04-26
• Results posted: 2019-04-26

Locations

7 sites across 1 country: Brazil